Medicaid best price reforms to enable innovative payment models for cell and gene therapies.

Casey Quinn,Michael Ciarametaro,Brian Sils,Sharon Phares,Mark Trusheim

Expert review of pharmacoeconomics & outcomes research（2023）

引用 3|浏览1

暂无评分

摘要

The Multiple Best Prices will likely enable VBPAs for many durable cell and gene therapies and larger payers. Further reforms may be needed to extend VBPAs to ultra-orphan conditions.

查看译文

关键词

Cell and gene therapies,Gene Therapies,Medicaid best price,Medicaid drug rebate program,health economics,health policy,outcomes-based contracts,patient access,payment innovation,value-based purchasing agreement

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要